• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>AstraZeneca PLC ADR

AstraZeneca PLC ADR

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. AstraZeneca : Study Shows Heart Drug Brilinta Cuts Blood-Clot Formation

    AstraZeneca : Study Shows Heart Drug Brilinta Cuts Blood-Clot Formation

  2. AstraZeneca Reports Positive Top-Line COPD Phase III Pinnacle Trial

    AstraZeneca Reports Positive Top-Line COPD Phase III Pinnacle Trial

  3. New Cancer Drugs: First Movers Will Win

    First movers, including Bristol-Myers, and firms that can aggregate a portfolio of immuno-oncology therapies will be positioned well.

  4. AstraZeneca Reaffirms its 2015 Earnings Guidance

    AstraZeneca Reaffirms its 2015 Earnings Guidance

  5. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

  6. UPDATE: FTSE 100 logs record closing high

    UPDATE: FTSE 100 logs record closing high

  7. LONDON MARKETS: FTSE 100 Logs Record Closing High

    LONDON MARKETS: FTSE 100 Logs Record Closing High

  8. Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery

    Asahi Kasei Pharma Selects Evotec as Its Partner for Ion Channel Drug Discovery

  9. PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack

    PEGASUS-TIMI 54 Study Shows That Long-Term Treatment with BRILINTA Reduced Thrombotic Cardiovascular Events in Patients with a History of Heart Attack

  10. LONDON MARKETS: FTSE 100 Rises As Drug Makers, SABMiller Advance

    LONDON MARKETS: FTSE 100 Rises As Drug Makers, SABMiller Advance

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.